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Summary
PRINCIPLES: Hypersplenism can be defined by thrombo-
cytopenia and/or neutropenia resulting from blood cell se-
questration in an enlarged spleen. In multimorbid patients
the differential diagnosis of cytopenia is challenging and
currently there is no established test for diagnosing hypers-
plenism.
METHODS: The epinephrine stimulation test (EST) meas-
ures changes in platelets, neutrophil counts and spleen size
following a subcutaneous epinephrine injection. We retro-
spectively analysed the results of EST in 228 patients.
RESULTS: Increases in neutrophils and platelets after epi-
nephrine injection were significantly greater in patients
with enlarged than in patients with normal size spleens.
Using cutoffs of low, intermediate and high confidence
EST was positive in 69.8% vs. 41.3% (low confidence),
49.6% vs. 17.4% (intermediate confidence) and 38.8% vs.
10.9% (high confidence) in patients with enlarged vs. nor-
mal size spleens. Changes in platelet and neutrophil counts
correlated with each other and with changes in spleen size,
confirming cell release from the spleen during EST. When
stratified according to the underlying diagnosis, patients
with liver disease had the strongest response to EST, pa-
tients with malignant haematological diseases the weakest.
In addition the response to EST was significantly related
to changes in platelet and neutrophil counts after splenec-
tomy, confirming the validity of our test. No serious side
effects occurred during EST.
CONCLUSION: When used in a large patient cohort, EST
is a safe and simple diagnostic test. In this exploratory
study EST is of value in evaluating patients with cytopenia
and a positive EST argues strongly for hypersplenism. Fu-
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ture studies should prospectively evaluate EST for the
management of patients with splenomegaly.
Key words: hypersplenism; cytopenia; neutropenia;
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Introduction
Splenic cytopenia refers to any cytopenia with a patho-
genesis involving the spleen. Whereby the spleen could
either actively degrade or sequester blood cells. For the lat-
ter mechanism the term hypersplenism is commonly used.
Hypersplenism can be defined by thrombocytopenia and/
or neutropenia resulting from blood cell sequestration in an
enlarged spleen. In some cases hypersplenism may also be
responsible for mild anaemia [1–3].
The vessel system of an enlarged spleen can be of con-
siderable size. Even under normal conditions some 30%
of platelets are stored within the spleen. In hypersplenism
this may increase to 90% [4, 5]. Importantly, platelets se-
questered within the spleen have a normal survival time [4,
5]. Pooling of neutrophils has also been suggested to occur
in an enlarged spleen [6–8]. In the absence of other patho-
logies the bone marrow is expected to be normal or hyper-
regenerative.
Evaluation of cytopenia in patients with an enlarged spleen
can be challenging and complex. Cytopenia may be due to
hypersplenism, but patients typically also suffer from an
underlying disease which could directly lead to cytopenia.
In addition, treatment may include drugs with haematolo-
gical side effects. For example, in patients with liver cir-
rhosis due to hepatitis C virus infection, thrombocytopenia
may be due to hypersplenism, impaired platelet production,
the chosen antiviral therapy and/or secondary conditions
including haemophagocytosis.
Therefore a simple diagnostic test to establish or rule out
hypersplenism would be beneficial. Initial studies to eval-
uate splenic sequestration have been done more than four
decades ago [4]. Subsequently the epinephrine stimulation
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test (EST), measuring changes in neutrophil and platelet
counts after subcutaneous injection of epinephrine in pa-
tients with suspected hypersplenism, was developed [9].
For neutrophils but not platelets an increase after epineph-
rine injection could also be due to demargination, redis-
tribution of neutrophils from the vessel wall to the circu-
lation. However, Schaffner et al. used the EST to demon-
strate a relationship between the haematological response
to epinephrine injection and splenic contraction [8, 10]. In
the last 23 years EST has been a standard diagnostic pro-
cedure to evaluate thrombocytopenia and/or neutropenia in
patients with an enlarged spleen in our tertiary care hos-
pital. In this study we summarise our experience with EST
and provide data of 228 patients evaluated by this proced-
ure. Within the limits of a retrospective analysis we set out
to explore the value of EST in predicting splenic sequest-
ration of platelets and neutrophils, and for the diagnosis of
hypersplenism.
Patients and methods
At our clinic between 1984 and 2006, 232 EST were car-
ried out in 228 patients. EST was performed as published
before [9]. In brief: after determination of baseline blood
count and spleen pole diameter using ultrasound technique,
0.5 mg epinephrine per m2 body surface area was injected
subcutaneously in the volar forearm. After epinephrine ad-
ministration spleen size was reassessed at 10 min and an-
other blood count was taken at 30 min. Percent changes
over baseline measurements in spleen size and blood count
were calculated. Criteria of low, intermediate and high con-
fidence were defined. The criterion for platelets was con-
sidered positive if in a thrombocytopenic patient an in-
crease of 30%, 40% or 50% above baseline was observed.
Similarly, the test criterion for neutrophils was regarded
as positive if in a neutropenic patient an increase of 60%,
100% or 150% was observed. EST was performed by this
standardised protocol on a routine basis in our outpatient
clinic. Indications for EST were workup of patients with
low platelet count and/or neutropenia with suspected hy-
persplenism or evaluation before splenectomy.
We retrospectively defined the following diagnostic groups
for further analysis: 1) unclear cytopenia (53 patients,
23%), 2) liver disease (n = 56; 25%), 3) malign haematolo-
gical diseases (n = 63; 28%) including hairy cell leukaemia
(HCL; n = 35, 15%), 4) benign haematological diseases (n
= 28; 12%) including immune thrombocytopenia (ITP, n =
21; 9%), 5) human immunodeficiency virus (HIV) infec-
tion (n = 16; 7%), 6) autoimmune diseases (n = 10; 4%) and
7) other conditions (2 patients, 1%).
Patients were also analysed according to spleen size. Thus
the splenomegaly group included patients with a documen-
ted spleen diameter of 13 cm or more (120 patients) or
a documented “large” or “huge” spleen size without spe-
cifications (9 patients). Similarly, the group with a nor-
mal spleen size included patients with a spleen diameter of
less than 11.5 cm (32 patients) or a documented “normal”
size spleen without specific information (2 patients). These
strict criteria for normal and large spleen size were chosen
since measurements of spleen size in more than one dimen-
sion and data for height and weight of patients were not
available in most cases. However, an analysis using 12 cm
as a lower cutoff yielded essentially identical results (not
shown).
Data of 23 patients were used to analyse blood counts be-
fore and after splenectomy,. For these patients, 2 blood
counts at least 2 months apart within the first 3 months
after splenectomy were available (in this data set blood
counts of 3 single time points were missing). Platelet and
neutrophil counts at both time points were highly correl-
ated (R2 = 0.51 for neutrophils and 0.44 for thrombocytes,
respectively in a linear regression analysis, Microsoft Ex-
cel). Therefore, an average of both values was calculated.
Eight patients with ITP were excluded from the analysis of
platelet and neutrophil counts after splenectomy.
For statistical calculations and graphs GraphPad Prism 5
was used. If not indicated otherwise, for correlation analys-
is Spearman’s rank correlation coefficients were calculated.
For groupwise comparisons the Mann-Whitney-U test or,
where appropriate, for a pairwise analysis the Wilcoxon
signed rank test was used. For comparison of test results
in different patient groups Fisher’s exact test was used.
An accurate estimation of splenic size requires sonograph-
ic measurements in three dimensions [11]. These data were
not available in all cases. Hence to estimate changes in
spleen volume we used the difference of the third power of
splenic length at time points 0 min and 10 min as an ap-
proximation. Since the calculation of Spearman’s rank cor-
relation coefficients only uses the ranks of measurements,
an exact volume is not needed for a valid correlation ana-
lysis. Retrospective data collection was done in agreement
with institutional policies and ethical guidelines of our in-
stitution (University Hospital of Zürich).
Results
Patient population
Our study summarises experience with EST in a large and
diverse patient cohort. In the course of 23 consecutive
years we performed 232 EST in 228 patients: 59% of our
patients were male; the age range of our study population
was 17–86 years. As shown in table 1, most of our patients
presented with splenomegaly, anaemia and thrombocyt-
openia; a considerable fraction also had neutropenia. Pa-
tients presented with various conditions including un-
defined cytopenias (23%), benign or malign haematologic-
al diseases (28%), liver disease (25%) and HIV infection
(7%). Our patient cohort is comparable to patients of a
large retrospective study at another tertiary care centre [12]
identifying haematological (57%), hepatic (11%) and in-
fectious conditions (19%) as the most frequent causes of
splenomegaly.
Side effects of EST
EST was well tolerated and no patient had to be hospit-
alised due to side effects. Unwanted effects of the epi-
nephrine injection occurred only rarely (9 patients, 3.9% of
all EST). We observed elevated blood pressure in 6 cases
(2.6% of all EST), headaches in 4 cases (1.7%), anxiety in
3 cases (1.3%), palpitations in 2 cases (0.9%), nausea in 1
case (0.4%) and chest pain in 1 case (0.4%). In all patients
Original article Swiss Med Wkly. 2012;141:w13324
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 2 of 11
symptoms responded immediately to phentolamine treat-
ment. In one of these patients (0.4% of all EST) epineph-
rine had been accidentally injected intravenously, leading
to nausea, headache, palpitations and elevated blood pres-
sure. Symptoms in this patient also responded promptly
to phentolamine and did not require hospitalisation. Our
data therefore confirm EST as a safe diagnostic procedure
Figure 1
Changes in spleen size and peripheral blood count during
epinephrine stimulation test (EST). Peripheral blood count and
spleen pole diameter were determined before and at 30 min or
10 min following epinephrine injection respectively. The box plot
indicates the median and the 25th and 75th percentile of the data
respectively. The whiskers represent the 5th and 95th percentile;
outliers are directly shown. Statistical analysis: Wilcoxon signed
rank test.
Figure 2
A: Changes in platelet and neutrophil counts in patients according
to spleen pole diameter. Statistical analysis: Mann Whitney U test;
box plot and whiskers as described in the legend for figure 1. B:
Higher frequency of positive tests in patients with an enlarged
spleen compared to patients with a normal size spleen. Different
criteria for the evaluation of EST were defined requiring either
neutrophils, platelets, one of each (“platelets OR neutrophils”) or
both (“platelets AND neutrophils”) to be above the respective cutoff.
Limits of low, intermediate ("mid") and high confidence of the test
were defined: For platelets an increase of 30%, 40% or 50%
respectively was chosen. For neutrophil counts these values were
60%, 100% or 150% respectively. Significance was calculated
using Fisher’s exact test.
which can be performed in patients with various diseases
and in an outpatient clinic.
Changes in spleen size and blood count during EST
During EST changes in spleen size, platelet, and neutrophil
counts as well as haemoglobin values were routinely as-
sessed according to our standardised protocol. The pole
diameter of the spleen was measured before the test and at
the 10-minute time point. As expected, pole diameter of the
spleen significantly decreased, on average by 2.2 cm, dur-
ing EST (fig. 1A). Simultaneously, neutrophil and throm-
bocyte counts increased significantly, on average by 86%
and 43% over baseline values respectively (fig. 1B, C). We
also noted a small increase in haemoglobin concentration
by 4.2% over baseline values (fig. 1D). Taken together, our
data are consistent with the assumption that platelets and
neutrophils are recruited from the spleen after epinephrine
stimulation.
Changes in spleen size during EST correlated significantly
with changes in neutrophil and platelet counts (table 2).
This correlation was more pronounced when instead of the
pole diameter estimated changes of the spleen volume were
correlated with neutrophil and platelet responses. Our data
therefore suggest that improvements in blood counts are
mediated by a decrease in spleen volume.
Different responses of EST according to spleen size
Not surprisingly, responses of EST differed according to
spleen size (fig. 2A). Our patient cohort mainly comprises
patients with enlarged spleens; however, patients with nor-
mal spleen sizes were also tested. EST in the latter patients
might have been ordered by the responsible physician to
evaluate the possibility of platelet or neutrophil trapping in
Figure 3
Platelet and neutrophil counts before and after splenectomy
according to results of EST. A, B: Thrombocyte and neutrophil
counts before and after splenectomy. C, D: Percent change in
thrombocyte and neutrophil counts after splenectomy according to
the result of EST at different confidence levels. The horizontal lines
in the graphs indicate the median of the respective data shown.
Significance was calculated using the Wilcoxon signed rank test (A,
B) or Mann Whitney U test (C, D) respectively.
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a normal size spleen as a cause of cytopenia. We defined
a patient group with a normal size spleen (diameter <11.5
cm) and a patient group with splenomegaly (diameter ≥13
cm). These strict criteria were chosen for an optimal separ-
ation of both patient groups. Our control group comprised
patients with unclear cytopenia (n = 12; 35%), ITP (n = 12;
35%), liver disease (n = 5; 15%), autoimmune diseases (n
= 3; 9%) as well as HIV and lymphoma (1; 3% each). The
splenomegaly group summarizes patients with liver disease
(n = 38; 29%), malign haematological disorders (n = 42;
33%, including 26 patients with hairy cell leukaemia), un-
clear cytopenia (n = 24; 19%), HIV (n = 15; 12%), benign
haematological disorders (n = 7; 5%, including 4 patients
with ITP), autoimmune disease (n = 2; 2%) and other con-
ditions (n = 1; 1%).
We compared relative changes in cell counts in both patient
groups during EST and noted a significantly stronger plate-
let and neutrophil response for splenomegaly patients com-
pared to patients with a normal spleen size (p = 0.0046 and
p = 0.001, respectively, fig. 2A).
Different confidence levels of EST
Due to lack of a gold standard we tried an internal valida-
tion of EST, using the splenomegaly group as the test group
and patients with normal size spleen as a control group.
Patients with a normal size spleen per definition would
not have hypersplenism. In a broader sense these patients
would have a low probability of a true positive test. In con-
trast, the group of patients with an enlarged spleen would
have a higher likelihood of a true positive test. A high ratio
of the percentage of positive tests in patients with a large
spleen to the percentage of positive tests in patients with
normal size spleens would indicate a good discrimination
of both groups, suggesting high specificity of the test.
We defined cutoff criteria of low, intermediate and high
confidence for a positive EST (fig. 2B). The limits for in-
creases in platelet and neutrophil counts of low confidence
were 30% and 60%, of intermediate confidence 40% and
100% and of high confidence 50% and 150% respectively.
We further combined these criteria in two different ways,
requiring either only one (“platelets OR neutrophils”) or
both values (“platelets AND neutrophils”) to be above the
cutoff value.
As shown in figure 2B, for all cutoff criteria the fraction
of positive test results for patients with an enlarged spleen
was consistently higher than for patients with a normal
size spleen. In most instances, differences reached statist-
ical significance; the only exceptions were several criter-
ia of high confidence for which the small number of posit-
ive tests precluded significance even though in the control
group no patient tested positive.
An increase in platelet counts above the respective cutoff
levels was frequently observed in splenomegaly patients,
consistent with a high sensitivity of this criterion. However,
the high number of positive tests at least for the low confid-
ence evaluation suggests a limited specificity. In contrast,
positive test results for changes in neutrophils occurred in-
frequently in patients with normal size spleens.
Generally, choosing the stricter criteria of higher confid-
ence improved discrimination of both groups (indicating
an improved specificity). This improvement was most pro-
nounced for increases in thrombocytes for which positive
results were observed in 62% vs. 41% (low confidence),
47% vs. 15% (intermediate confidence) and 38% vs. 12%
(high confidence) of patients with enlarged and normal
spleens, respectively.
In our evaluation, for the most stringent mode of analysis a
high specificity is likely since an increase of both, throm-
bocytes and neutrophils above cutoff occurred in 21%,
12% and 8% of patients with splenomegaly but in no pa-
tient with a normal spleen (“platelets AND neutrophils” in
fig. 2B). However, strict criteria might also decrease the
sensitivity of our test, as indicated by the low number of
positive tests in patients with large spleens under these con-
ditions.
In our clinical practice and in the following evaluations
we required only one criterion to be above the threshold
(evaluation “platelets OR neutrophils” in fig. 2B). In our
patient cohort EST was thus positive in 69.8% vs. 41.3%
(low confidence), 49.6% vs. 17.4% (intermediate confiden-
ce) and 38.8% vs. 10.9% (high confidence) in patients with
enlarged vs. normal size spleen.
Response of EST in different diagnosis subgroups
Stratifying splenomegaly patients according to the underly-
ing diagnosis revealed important differences between spe-
cific patient groups (table 3). For patients with splenomeg-
aly and liver disease EST was significantly more often
positive than for the remaining splenomegaly patients at
all confidence levels (low confidence: 87% vs. 63%, p =
0.0063; intermediate confidence: 71% vs. 41%, p = 0.002;
high confidence: 58% vs. 31%, p = 0.0054). Moreover,
in patients with liver disease the correlation of changes in
spleen volume vs. changes in platelets (r = 0.52, p <0.0005)
and neutrophils (r = 0.47, p <0.002) was more pronounced
than in the whole patient group (compare table 2). We
conclude that haematological abnormalities in hypersplenic
patients with liver diseases were especially responsive to
epinephrine.
In contrast, in the subgroup of patients with splenomegaly
and malign haematological disorders or hairy cell leuk-
aemia, EST was significantly less often positive (table 3).
Importantly, an analysis of the frequency of positive tests in
diagnostic subgroups yielded similar differences if all pa-
tients including patients with normal size spleen were con-
sidered. However, significance levels tended to be lower,
probably due to contamination of patients with a normal
size spleen and negative test results (table S1).
Validation of EST in patients undergoing splenectomy
Haematological changes after splenectomy would be an in-
dependent validation of EST. 23 patients were evaluated
with EST before splenectomy. 8 patients with ITP were ex-
cluded since splenectomy is a known treatment for ITP and
would be expected to increase platelet counts independ-
ently of effects on splenic platelet sequestration. For the
remaining patients, blood counts before and after splenec-
tomy were compared (for details see Patients and Meth-
ods section). As expected, splenectomy caused a strong and
significant increase in platelet and neutrophil counts (p =
0.0001, p = 0.03, respectively; fig. 3A, B).
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EST results were predictive of increases in neutrophil and
platelet counts after splenectomy. We stratified patients ac-
cording to EST results (fig. 3C, D). With the least strin-
gent criteria for EST evaluation, we did not notice any dif-
ferences between patients with positive and negative EST.
In contrast, with criteria of high confidence, patients with
positive test results showed stronger improvement in cell
counts than patients with negative test results. This increase
was significant for changes in platelet counts (p = 0.0256)
and neutrophils (p = 0.036). Significance also remained in-
tact in the whole splenectomy group including the 8 pa-
tients with ITP (data not shown). Using criteria of inter-
mediate confidence, significant differences were only ob-
served for changes in neutrophil counts (p = 0.0488). Taken
together, EST results are significantly related to changes in
cell counts after splenectomy.
Discussion
The current study summarises 23 years of experience with
the epinephrine stimulation test at our institution. We
provide clinical, sonographic and haematological data for
228 patients. Seminal studies of EST were done up to 30
years ago with very small patient cohorts [8, 10]. Our data
now provide a detailed analysis of a much larger patient co-
hort.
Our data confirm and extend our knowledge of hypersplen-
ism. Hypersplenism does not translate into dramatic his-
topathological findings [13], and physiological studies are
required to clarify pathogenesis. Previously, a negative cor-
relation of spleen size and haematological parameters has
been observed in various settings, e.g. in Gaucher’s disease
[14] and liver cirrhosis [15]. In our study, changes in blood
cell counts correlate with changes in spleen diameter [10]
Table 1: Clinical presentation of patients with splenomegaly, normal size spleen and the whole patient cohort evaluated by the epinephrine stimulation test: spleen size and
peripheral blood count before epinephrine stimulation test. Our patient cohort also comprised 27 patients with borderline size spleen (≥11.5 cm but <13 cm) as well as 38
patients without documented spleen size.
Spleen size Splenomegaly
≥13 cm
n = 129
Normal
<11.5 cm
n = 34
All
n = 228
Haemoglobin values
Anaemia
(<11.7 g/dL in ♀ or <13.4 g/dL in ♂)
Normal
Not documented
87
35
7
10
21
3
132
80
16
Thrombocytes
Thrombocytopenia (<150000 G/L)
Thrombocytosis (>450000 G/L)
Normal values
122
0
7
25
0
9
195
1
32
Neutrophiles
Neutropenia (<1500 G/L)
Neutrophilia (>8500 G/L)
Normal values
60
2
67
9
4
21
97
10
121
Table 2: Correlation analysis of percent changes in platelet, neutrophil and spleen parameters. Significant differences are indicated in green (p <0.05), very significant
differences in red (p <0.01); Spearman's rank correlation test.
Percent change in platelet count Percent change in neutrophil count
Percent change of neutrophil count r = 0.65
p <0.0001
Spleen length r = 0.19
p = 0.01
r = 0.28
p = 0.0001
Change in spleen length r = 0.18
p = 0.023
r = 0.25
p = 0.0017
Approximate change in spleen volume r = 0.22
p = 0.0063
r = 0.31
p <0.0001
Table 3: Positive tests in different diagnosis groups. Patients were analysed according to their underlying diagnosis. The percentage of patients with splenomegaly is
given; the subsequent analysis is restricted to these splenomegaly patients. For each level of confidence the number of positive tests is given and significance of any
difference versus the remaining patient population calculated (Fisher’s exact test). Significant differences are indicated in green (p <0.05), very significant differences in red
(p <0.01).
All patients Splenomegaly patients
Splenomegaly Positive low
confidence
Positive intermediate
confidence
Positive
high
confidence
n n n n n
All 228 129; 57% 90; 70% 64; 50% 50; 39%
Malignant
haematological
63 42
67%
24; 57%
p = 0.041
15; 36%
p = 0.039
9; 21%
p = 0.0066
HCL
subgroup
35 26
74%
14; 54%
n.s.
8; 31%
p = 0.047
4; 15%
p = 0.0066
Liver disease 56 38
68%
33; 87%
p = 0.0063
27; 71%
p = 0.002
22; 58%
p = 0.0054
Original article Swiss Med Wkly. 2012;141:w13324
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 5 of 11
and correlate even more strongly with estimated changes in
spleen volume after epinephrine injection, suggesting the
spleen as the source for the release of neutrophils and plate-
lets.
Epinephrine also leads to demarginalisation of granulo-
cytes from the walls of blood vessels. However, in our
study an increase in neutrophil counts above cutoff levels
was only infrequently observed in the patient group with
a normal size spleen, making it unlikely that demargin-
alisation contributes in a major way to a positive EST
result. Furthermore, in our analysis, changes in thrombo-
cyte and granulocyte values showed a strong correlation,
consistent with a common mechanism for the increase of
both cell types after epinephrine injection [10]. However,
since the majority of all patients and even 53% of patients
with splenomegaly did not present neutropenia at baseline,
hypersplenism might affect the thrombocyte count more
strongly than the neutrophil count. Nevertheless, the study
thus confirms the view that a reserve pool of thrombocytes
and granulocytes exists which is larger in hypersplenism
and stored to a considerable degree in the spleen [10].
Epinephrine injection in turn causes splenic contraction
and release of thrombocytes and neutrophils.
Our results are important in the light of more recent reports
which emphasise the role of thrombopoietin for thrombo-
cytopenia in splenomegaly due to liver disease [1]. Our
data do not exclude a role for haematopoietic growth
factors, but offer further evidence that splenic sequestration
makes a relevant contribution to the pathogenesis of throm-
bocytopenia in splenomegaly, most probably as one aspect
of a multifactorial disease.
Compared to other diagnosis groups, EST was most fre-
quently positive in patients with liver disease. In this situ-
ation splenomegaly results from increased portal pressure
and venous stasis in the spleen. These changes of portal
and splenic blood flow are probably important, since
epinephrine-dependent changes were less pronounced in
malignant haematological diseases when the spleen is in-
filtrated with leukaemia or lymphoma cells. It is likely that
the latter process leads to a decrease in the intravascular
volume of the otherwise enlarged spleen and a less pro-
nounced response of EST, as indicated by the lesser fre-
quency of pathological EST results in patients with malig-
nant haematological diseases, including HCL (table 3).
Hypersplenism is known to be an important aspect of liver
disease and has prognostic significance for survival [16].
Hypersplenism in this context could be reversed by splen-
ectomy or orthotopic liver transplantation [17] but also at-
tenuated by placement of a transjugular intrahepatic por-
tosystemic shunt [18, 19] or by partial splenic embolisation
[20–23]. In a recent randomised controlled trial comparing
splenectomy and radiofrequency ablation (RFA) [24] a
similar correction of blood counts in the RFA group com-
pared to the splenectomy group was observed if more than
70% of the splenic volume was ablated. Future manage-
ment of thrombocytopenia in liver disease might be orien-
ted towards the contribution of pathogenetic factors such
as splenic sequestration or thrombopoietin deficiency [25].
Thereby, a role of EST for the selection of patients for dif-
ferent therapeutic interventions could be tested.
We propose different cutoff values for EST defined by
comparing platelet and neutrophil changes for patients with
normal and enlarged spleens. It is important to note that an
increase in neutrophils above cutoff levels was infrequently
observed in the control group with a normal size spleen,
suggesting a high specificity of this criterion. However, an
increase in platelets after epinephrine injection was also
observed in patients without splenomegaly (even though
less frequently), indicating the less than optimal specificity
of this criterion. We can think of two reasons for such false
positive tests: i) significant trapping and release of blood
cells may also occur in a normal size spleen; this would not
constitute hypersplenism, since the diagnostic criterion of
splenomegaly would be missing but might have the same
haematological consequences; ii) individual physiological
reactions of a normal spleen to epinephrine might vary; we
are currently unable to distinguish between the two possib-
ilities.
We independently confirmed cutoff values and validity of
EST using data of patients who underwent splenectomy.
Splenectomy can correct cytopenia due to hypersplenism
[26, 27]. As expected of a diagnostic test for hypersplen-
ism, increases in platelets and neutrophils after splenec-
tomy were more marked in patients with positive test res-
ults if strict diagnostic criteria were used.
Our study has several strengths but also important limita-
tions. The strength of our study is the large patient popu-
lation, which compares favourably with former studies of
fewer than 20 patients [8, 10]. Importantly, the size and
diversity of our patient cohort, which includes many age
groups and underlying diseases, allows us to conclude that
EST is a safe diagnostic procedure. Furthermore, there has
been a paucity of publications addressing diagnostic pro-
Table S1: Positive tests in different diagnosis groups. Patients were analysed according to their underlying diagnosis in a similar analysis to that presented in table 3;
however, the whole patient population, including patients with normal size spleens, was considered. For each level of confidence the number of positive tests is given and
significance of any difference versus the remaining patient population calculated (Fisher’s exact test). Significant differences are indicated in green (p <0.05), very
significant differences in red (p <0.01).
Positive low
confidence
Positive intermediate
confidence
Positive high
confidence
Number n; % n; % n; %
All 228 138; 61% 87; 38% 67; 29%
Malignant
hematological
63 37 59%
n.s.
19; 30%
n.s.
12; 19%
n.s.
HCL
subgroup
35 19; 54%
n.s.
9; 26%
n.s.
4; 11%
n.s.
Liver disease 56 41; 73%
p = 0.028
33; 59%
p = 0.0004
26; 46%
p <0.0001
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cedures of hypersplenism, and diagnostic alternatives to
EST are lacking.
A limitation of our study is the retrospective study design.
Diagnostic criteria for a positive test were also retrospect-
ively defined. Historical cutoff values for EST were estab-
lished in a small cohort of healthy patients, which might
not be representative of patients with cytopenia not due to
hypersplenism. For these reasons our results require pro-
spective validation in a new patient group. Also, the major-
ity of the whole patient population and even the majority of
patients with an enlarged spleen had normal baseline neut-
rophil values. This reflects either a referral bias or a (in our
opinion more likely) lower risk of neutropenia in hypers-
plenic patients. In any case, fewer data are available within
our cohort for evaluation of EST for the diagnosis of hy-
persplenic neutropenia. Another important limitation is the
lack of an accepted diagnostic gold standard for hypers-
plenism. Hence no numbers for sensitivity and specificity
of EST can be calculated, making a quantitative interpret-
ation of EST difficult. A third limitation is the partially in-
complete data set, with documentation of spleen diamet-
ers in 38 (16.7%) of patients missing. However, due to the
large number of remaining patients, this incomplete report-
ing is unlikely to change our analysis. Finally, even though
our patient cohort is large, for some diagnostic subgroups
and for the analysis of patients undergoing splenectomy the
numbers are small and the heterogeneity of the study pop-
ulation remains a concern.
In our clinical experience during the last 23 years EST
has been useful on many occasions. EST was employed
for exclusion of predominant hyporegenerative thrombo-
cytopenia in the setting of e.g. an HIV-infected patient with
highly active antiretroviral therapy, or in a patient with liv-
er disease under drug treatment. In several of these cases
a strong EST response allowed the patient to be managed
without bone marrow examination. However, considering
the above-mentioned limitations of our study EST should
always be considered as one piece in a diagnostic puzzle
and interpreted within the clinical context.
Whether thrombocytopenia due to hypersplenism confers
a lesser bleeding risk than thrombocytopenia in a different
setting is unknown. According to older data, thrombocytes
sequestered within the enlarged spleen are available, func-
tionally active and in equilibrium with the pool of freely
circulating platelets [4, 10]. Recruitment of these platelets
to the circulation during a critical bleeding episode would
be expected. It was speculated that EST would simulate the
stress of a shock situation since changes in thrombocytes
and granulocytes after EST closely resemble changes dur-
ing physical exercise [8]. However, neither older studies
nor our data directly address the risk of bleeding and a pre-
dictive value of EST results for future bleeding episodes
has not been demonstrated.
In conclusion, for the management of a patient with splen-
omegaly the lack of an established test directly measuring
splenic sequestration is a major clinical limitation. We be-
lieve this question should be addressed in a systematic
prospective trial which should include EST, scintigraphy
studies of radiolabelled thrombocytes, bone marrow ex-
aminations and measurements of haematopoietic growth
factors. Moreover, long term follow-up data of these pa-
tients should be acquired. So while our data do not close
the gap for the diagnosis of hypersplenism, they provide
the basis for a better study of this condition.
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Figures (large format)
Figure 1
Changes in spleen size and peripheral blood count during epinephrine stimulation test (EST). Peripheral blood count and spleen pole diameter
were determined before and at 30 min or 10 min following epinephrine injection respectively. The box plot indicates the median and the 25th and
75th percentile of the data respectively. The whiskers represent the 5th and 95th percentile; outliers are directly shown. Statistical analysis:
Wilcoxon signed rank test.
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Figure 2
A: Changes in platelet and neutrophil counts in patients according to spleen pole diameter (Mann Whitney U test); box plot and whiskers as
described in the legend for figure 1. B: Higher frequency of positive tests in patients with an enlarged spleen compared to patients with a normal
size spleen. Different criteria for the evaluation of EST were defined requiring either neutrophils, platelets, one of each (“platelets OR
neutrophils”) or both (“platelets AND neutrophils”) to be above the respective cutoff. Limits of low, intermediate ("mid") and high confidence of
the test were defined: For platelets an increase of 30%, 40% or 50% respectively was chosen. For neutrophil counts these values were 60%,
100% or 150% respectively. Significance was calculated using Fisher’s exact test.
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Figure 3
Platelet and neutrophil counts before and after splenectomy according to results of EST. A, B: Thrombocyte and neutrophil counts before and
after splenectomy. C, D: Percent change in thrombocyte and neutrophil counts after splenectomy according to the result of EST at different
confidence levels. The horizontal lines in the graphs indicate the median of the respective data shown. Significance was calculated using the
Wilcoxon signed rank test (A, B) or Mann Whitney U test (C, D) respectively.
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